Author | Amy P. Abernethy, MD, PhD


It's Time to Have ‘The Talk’: Cost Communication and Patient-Centered Care

June 15, 2014

Barriers to cost discussions fall into three categories: inaccessible cost data, ethical concerns, and insufficient training.

A Comparison of FDA and EMA Drug Approval: Implications for Drug Development and Cost of Care

December 15, 2013

The development and approval of oncology therapeutics has been facilitated by the cooperation and coordination of regulatory practices between the EMA and the FDA. However, there continue to be important differences between the decisions of the two agencies.

Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?

April 15, 2013

Just as high-quality research has focused on limiting the physical toxicity resulting from successful treatment, future research should focus on mitigating the negative effects of financial toxicity without affecting disease-related outcomes.

Financial Toxicity, Part I: A New Name for a Growing Problem

February 15, 2013

Costs of care continue to rise; new cancer drugs are more expensive than ever before, and more patients are being treated with these drugs. While patients and claims datasets consistently report an association between financial burden and quality of care, the impact on traditional disease-related outcomes-survival, for example-have not been assessed.